Headache Prevalence and Phenotype in Myelin Oligodendrocyte Glycoprotein Antibody -Associated Disease (MOGAD)

计划入组 25 人 · 首次发布于 2026 年 3 月 18 日

Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

计划入组 102 人 · 首次发布于 2024 年 6 月 11 日

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

计划入组 132 人 · 首次发布于 2022 年 3 月 9 日

MOG-CAR-Tregs cell therapy (Sangamo Therapeutics)

Myelin oligodendrocyte glycoprotein gene therapy (University of Florida)

anti-myelin oligodendrocyte glycoprotein CAR Treg-cell therapy (multiple sclerosis)

Cambridge Antibody Technology

New Zealand

Associated Capital

United States

Latticon Antibody Therapeutics, Inc

United States

Phase 3 MOGwAI Trial Investigates Azathioprine for First-Line MOGAD Treatment

IL-6 Receptor Blockers Show Promise for Preventing Relapses in Rare Autoimmune Neurological Disorder MOGAD

ENSPRYNG Achieves 68% Reduction in MOGAD Relapses in Pivotal Phase III Trial